首页> 美国卫生研究院文献>Frontiers in Pharmacology >Probiotics Supplementation Therapy for Pathological Neonatal Jaundice: A Systematic Review and Meta-Analysis
【2h】

Probiotics Supplementation Therapy for Pathological Neonatal Jaundice: A Systematic Review and Meta-Analysis

机译:病理性新生儿黄疸的益生菌补充疗法:系统评价和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: Neonatal jaundice is a relatively prevalent disease and affects approximately 2.4–15% newborns. Probiotics supplementation therapy could assist to improve the recovery of neonatal jaundice, through enhancing immunity mainly by regulating bacterial colonies. However, there is limited evidence regarding the effect of probiotics on bilirubin level in neonates. Therefore, this study aims at systematically evaluating the efficacy and safety of probiotics supplement therapy for pathological neonatal jaundice.>Methods: Databases including PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wan Fang Database (Wan Fang), Chinese Biomedical Literature Database (CBM), VIP Database for Chinese Technical Periodicals (VIP) were searched and the deadline is December 2016. Randomized controlled trials (RCTs) of probiotics supplementation for pathological neonatal jaundice in publications were extracted by two reviewers. The cochrane tool was applied to assessing the risk of bias of the trials. The extracted information of RCTs should include efficacy rate, serum total bilirubin level, time of jaundice fading, duration of phototherapy, duration of hospitalization, adverse reactions. The main outcomes of the trials were analyzed by Review Manager 5.3 software. The relative risks (RR) or mean difference (MD) with a 95% confidence interval (CI) was used to measure the effect.>Results: 13 RCTs involving 1067 neonatal with jaundice were included in the meta-analysis. Probiotics supplementation treatment showed efficacy [RR: 1.19, 95% CI (1.12, 1.26), P < 0.00001] in neonatal jaundice. It not only decreased the total serum bilirubin level after 3day [MD: −18.05, 95% CI (−25.51, −10.58), P < 0.00001], 5day [MD: -23.49, 95% CI (−32.80, −14.18), P < 0.00001], 7day [MD: −33.01, 95% CI (−37.31, −28.70), P < 0.00001] treatment, but also decreased time of jaundice fading [MD: −1.91, 95% CI (−2.06, −1.75), P < 0.00001], as well as the duration of phototherapy [MD: −0.64, 95% CI (−0.84, −0.44), P < 0.00001] and hospitalization [MD: −2.68, 95% CI (−3.18, −2.17), P < 0.00001], when compared with the control group. Additionally, no serious adverse reaction was reported.>Conclusion: This meta-analysis shows that probiotics supplementation therapy is an effective and safe treatment for pathological neonatal jaundice.
机译:>背景:新生儿黄疸是一种相对流行的疾病,约占2.4-15%的新生儿。益生菌补充疗法可通过主要通过调节细菌菌落来增强免疫力,从而有助于改善新生儿黄疸的恢复。但是,关于益生菌对新生儿胆红素水平影响的证据有限。因此,本研究旨在系统地评估益生菌补充疗法对病理性新生儿黄疸的疗效和安全性。>方法:数据库包括PubMed,Embase,Cochrane图书馆,中国国家知识基础设施(CNKI),万方数据库(Wan Fang),中国生物医学文献数据库(CBM),中国技术期刊VIP数据库(VIP)进行了检索,截止日期为2016年12月。两种方法提取了补充益生菌补充病理性新生儿黄疸的随机对照试验(RCT)。评论者。 Cochrane工具用于评估试验偏倚的风险。 RCT的提取信息应包括疗效率,血清总胆红素水平,黄疸褪色时间,光疗时间,住院时间,不良反应。试验的主要结果通过Review Manager 5.3软件进行了分析。相对危险度(RR)或均值差异(MD)和95%置信区间(CI)用来衡量效果。>结果:13项涉及1067例黄疸新生儿的随机对照研究被纳入了荟萃分析分析。益生菌补充治疗对新生儿黄疸的疗效[RR:1.19,95%CI(1.12,1.26),P <0.00001]。它不仅降低了3天后的总血清胆红素水平[MD:-18.05,95%CI(−25.51,−10.58),P <0.00001],5天[MD:-23.49,95%CI(−32.80,-14.18) ,P <0.00001],治疗7天[MD:−33.01,95%CI(−37.31,−28.70),P <0.00001]治疗,但黄疸褪色时间缩短[MD:−1.91,95%CI(−2.06, -1.75),P <0.00001]以及光疗的持续时间[MD:-0.64,95%CI(-0.84,-0.44),P <0.00001]和住院治疗[MD:-2.68,95%CI(- 3.18,−2.17),P <0.00001],与对照组相比。此外,没有严重不良反应的报道。>结论:这项荟萃分析表明,益生菌补充疗法是治疗新生儿病理性黄疸的一种有效且安全的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号